4
Changes in Ownership
Entrada Therapeutics, Inc. Filed Acc 0001689375-24-000068
Chief Financial Officer sold 6,000 shares at an average $19.99 ($119,948)
- Chief Financial Officer acquired 6,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| WENTWORTH KORY JAMES Chief Financial Officer | 2024-11-29 | Option exercise 10b5-1 | +1,000 | $2.10 | $2,100 | 74,849 | D |
| WENTWORTH KORY JAMES Chief Financial Officer | 2024-11-29 | Sale 10b5-1 | −1,000 | $19.97 | $19,970 | 73,849 | D |
| WENTWORTH KORY JAMES Chief Financial Officer | 2024-12-02 | Option exercise 10b5-1 | +5,000 | $2.10 | $10,500 | 78,849 | D |
| WENTWORTH KORY JAMES Chief Financial Officer | 2024-12-02 | Sale 10b5-1 | −5,000 | $20.00 | $99,978 | 73,849 | D |
| Derivatives | |||||||
| WENTWORTH KORY JAMES Chief Financial Officer | 2024-11-29 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,000 | 36,157 | D | ||
| WENTWORTH KORY JAMES Chief Financial Officer | 2024-12-02 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 31,157 | D | ||
| Open-market sales · 6,000 sh · avg $19.99 · $119,948 | |||||||
Loading xslF345X05/wk-form4_1733264776.xml…